AP
Aptevo Therapeutics Inc.
APVO · NASDAQ
$1.84 -2.13% (-$0.04)
1M -23.65%
Market Cap $2.29M
P/E Ratio -
Div. Yield -
ROE 201.49%
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.38x
PEG N/A
P/S N/A
Growth
19 /100
Declining Book val. growth 1.11%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 201.49%
ROA 181.89%
Asset turnover 0.00x
Debt
79 /100
Low Current ratio 2.08x
Debt/Equity 0.70x
Net debt/EBITDA N/A
Stability
10 /100
Unstable EPS volatility 166.54%
Profitable years 0
Beta 1.61x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na APVO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jeffrey G. Lamothe
Employees
33
Headquarters
Seattle
Nadcházející události
05 LIS
Earnings
Upcoming earnings report